Logo image of HSCS

HEARTSCIENCES INC (HSCS) Stock Fundamental Analysis

NASDAQ:HSCS - Nasdaq - US42254E3027 - Common Stock - Currency: USD

3.69  -0.12 (-3.17%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to HSCS. HSCS was compared to 190 industry peers in the Health Care Equipment & Supplies industry. HSCS has a bad profitability rating. Also its financial health evaluation is rather negative. HSCS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HSCS has reported negative net income.
HSCS had a negative operating cash flow in the past year.
HSCS had negative earnings in each of the past 5 years.
HSCS had a negative operating cash flow in each of the past 5 years.
HSCS Yearly Net Income VS EBIT VS OCF VS FCFHSCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

HSCS's Return On Assets of -84.93% is on the low side compared to the rest of the industry. HSCS is outperformed by 80.32% of its industry peers.
HSCS's Return On Equity of -164.44% is on the low side compared to the rest of the industry. HSCS is outperformed by 72.87% of its industry peers.
Industry RankSector Rank
ROA -84.93%
ROE -164.44%
ROIC N/A
ROA(3y)-164.63%
ROA(5y)-163.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HSCS Yearly ROA, ROE, ROICHSCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

Looking at the Gross Margin, with a value of 67.31%, HSCS is in the better half of the industry, outperforming 72.87% of the companies in the same industry.
In the last couple of years the Gross Margin of HSCS has grown nicely.
The Profit Margin and Operating Margin are not available for HSCS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.97%
GM growth 5YN/A
HSCS Yearly Profit, Operating, Gross MarginsHSCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

3

2. Health

2.1 Basic Checks

HSCS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HSCS has been reduced compared to 1 year ago.
HSCS has a better debt/assets ratio than last year.
HSCS Yearly Shares OutstandingHSCS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
HSCS Yearly Total Debt VS Total AssetsHSCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

HSCS has an Altman-Z score of -14.58. This is a bad value and indicates that HSCS is not financially healthy and even has some risk of bankruptcy.
HSCS's Altman-Z score of -14.58 is on the low side compared to the rest of the industry. HSCS is outperformed by 84.04% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that HSCS is not too dependend on debt financing.
HSCS has a better Debt to Equity ratio (0.01) than 66.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -14.58
ROIC/WACCN/A
WACC8.61%
HSCS Yearly LT Debt VS Equity VS FCFHSCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M -2M 4M -4M 6M -6M

2.3 Liquidity

HSCS has a Current Ratio of 1.72. This is a normal value and indicates that HSCS is financially healthy and should not expect problems in meeting its short term obligations.
HSCS has a worse Current ratio (1.72) than 71.81% of its industry peers.
A Quick Ratio of 1.52 indicates that HSCS should not have too much problems paying its short term obligations.
HSCS has a Quick ratio of 1.52. This is comparable to the rest of the industry: HSCS outperforms 40.43% of its industry peers.
Industry RankSector Rank
Current Ratio 1.72
Quick Ratio 1.52
HSCS Yearly Current Assets VS Current LiabilitesHSCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 59.52% over the past year.
HSCS shows a strong growth in Revenue. In the last year, the Revenue has grown by 257.69%.
Measured over the past years, HSCS shows a very negative growth in Revenue. The Revenue has been decreasing by -10.10% on average per year.
EPS 1Y (TTM)59.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.81%
Revenue 1Y (TTM)257.69%
Revenue growth 3Y-10.1%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 24.90% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 358.08% on average over the next years. This is a very strong growth
EPS Next Y81.01%
EPS Next 2Y36.7%
EPS Next 3Y24.9%
EPS Next 5YN/A
Revenue Next Year-15.68%
Revenue Next 2Y495.09%
Revenue Next 3Y358.08%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HSCS Yearly Revenue VS EstimatesHSCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 1M 2M 3M 4M 5M
HSCS Yearly EPS VS EstimatesHSCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

HSCS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HSCS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HSCS Price Earnings VS Forward Price EarningsHSCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HSCS Per share dataHSCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

HSCS's earnings are expected to grow with 24.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.7%
EPS Next 3Y24.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HSCS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HEARTSCIENCES INC

NASDAQ:HSCS (2/21/2025, 8:26:03 PM)

3.69

-0.12 (-3.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)12-16 2024-12-16/amc
Earnings (Next)03-13 2025-03-13/amc
Inst Owners1.16%
Inst Owner Change-40.16%
Ins Owners4.96%
Ins Owner Change0%
Market Cap3.62M
Analysts82.5
Price Target13.77 (273.17%)
Short Float %3.78%
Short Ratio0.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.71%
Min EPS beat(2)-5%
Max EPS beat(2)8.42%
EPS beat(4)2
Avg EPS beat(4)-93.12%
Min EPS beat(4)-426.89%
Max EPS beat(4)50.98%
EPS beat(8)4
Avg EPS beat(8)-52.25%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-11.53%
EPS NQ rev (3m)21%
EPS NY rev (1m)-7.01%
EPS NY rev (3m)-7.01%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-96.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 194.42
P/FCF N/A
P/OCF N/A
P/B 0.9
P/tB 1.49
EV/EBITDA N/A
EPS(TTM)-26.72
EYN/A
EPS(NY)-6.68
Fwd EYN/A
FCF(TTM)-8.17
FCFYN/A
OCF(TTM)-8.04
OCFYN/A
SpS0.02
BVpS4.1
TBVpS2.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.93%
ROE -164.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.31%
FCFM N/A
ROA(3y)-164.63%
ROA(5y)-163.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.97%
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 338.25%
Cap/Sales 672.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.72
Quick Ratio 1.52
Altman-Z -14.58
F-Score3
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)174.78%
Cap/Depr(5y)108.86%
Cap/Sales(3y)346.2%
Cap/Sales(5y)211.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.81%
EPS Next Y81.01%
EPS Next 2Y36.7%
EPS Next 3Y24.9%
EPS Next 5YN/A
Revenue 1Y (TTM)257.69%
Revenue growth 3Y-10.1%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-15.68%
Revenue Next 2Y495.09%
Revenue Next 3Y358.08%
Revenue Next 5YN/A
EBIT growth 1Y-3.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.04%
EBIT Next 3Y2.01%
EBIT Next 5YN/A
FCF growth 1Y-58.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.02%
OCF growth 3YN/A
OCF growth 5YN/A